173 related articles for article (PubMed ID: 26643330)
1. Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.
Yang ML; Uhrig J; Vu K; Singapuri A; Dennis M; Gelli A; Thompson GR
Antimicrob Agents Chemother; 2015 Dec; 60(3):1202-7. PubMed ID: 26643330
[TBL] [Abstract][Full Text] [Related]
2. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.
Sykes JE; Hodge G; Singapuri A; Yang ML; Gelli A; Thompson GR
Med Mycol; 2017 Jun; 55(4):396-401. PubMed ID: 28339594
[TBL] [Abstract][Full Text] [Related]
3. Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment.
Chang M; Sionov E; Khanal Lamichhane A; Kwon-Chung KJ; Chang YC
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378705
[No Abstract] [Full Text] [Related]
4. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
5. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA
Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215
[TBL] [Abstract][Full Text] [Related]
6. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
Gast CE; Basso LR; Bruzual I; Wong B
Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
[TBL] [Abstract][Full Text] [Related]
7. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
8. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
10. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.
Santos JR; Holanda RA; Frases S; Bravim M; Araujo Gde S; Santos PC; Costa MC; Ribeiro MJ; Ferreira GF; Baltazar LM; Miranda AS; Oliveira DB; Santos CM; Fontes AC; Gouveia LF; Resende-Stoianoff MA; Abrahão JS; Teixeira AL; Paixão TA; Souza DG; Santos DA
PLoS One; 2014; 9(11):e112669. PubMed ID: 25392951
[TBL] [Abstract][Full Text] [Related]
12. Heteroresistance of Cryptococcus gattii to fluconazole.
Varma A; Kwon-Chung KJ
Antimicrob Agents Chemother; 2010 Jun; 54(6):2303-11. PubMed ID: 20385871
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains.
Silva DC; Martins MA; Szeszs MW; Bonfietti LX; Matos D; Melhem MS
Diagn Microbiol Infect Dis; 2012 Apr; 72(4):332-9. PubMed ID: 22341512
[TBL] [Abstract][Full Text] [Related]
15. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
16. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.
Sanguinetti M; Posteraro B; La Sorda M; Torelli R; Fiori B; Santangelo R; Delogu G; Fadda G
Infect Immun; 2006 Feb; 74(2):1352-9. PubMed ID: 16428784
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole.
Posteraro B; Sanguinetti M; Sanglard D; La Sorda M; Boccia S; Romano L; Morace G; Fadda G
Mol Microbiol; 2003 Jan; 47(2):357-71. PubMed ID: 12519188
[TBL] [Abstract][Full Text] [Related]
18. Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.
Mendes FE; Oliveira LV; Faria ES; Alvarenga DG; Pinto MR; Taborda CP; Soares BM; Cisalpino PS; Santos DA
Eur J Clin Microbiol Infect Dis; 2010 Dec; 29(12):1525-32. PubMed ID: 20803047
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
Lahiri Mukhopadhyay S; Bahubali VH; Manjunath N; Swaminathan A; Maji S; Palaniappan M; Parthasarathy S; Chandrashekar N
Mycoses; 2017 Nov; 60(11):749-757. PubMed ID: 28736880
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis.
Santos JR; César IC; Costa MC; Ribeiro NQ; Holanda RA; Ramos LH; Freitas GJ; Paixão TA; Pianetti GA; Santos DA
Eur J Pharm Sci; 2016 Sep; 92():235-43. PubMed ID: 27235581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
